3659

Farmacia Hospitalaria
ISSN: 1130-6343
ISSN: 2171-8695
Grupo Aula Médica

Chimeric antigen-receptor (CAR) T cells: The revtion of the cell and personalized therapy for cancer

Briones-Meijide, Javier

Chimeric antigen-receptor (CAR) T cells: The revtion of the cell and personalized therapy for cancer
Farmacia Hospitalaria, vol. 43, no. 6, 2019
Grupo Aula Médica
Available in: http://www.redalyc.org/articulo.oa?id=365963307001
DOI: 10.7399/fh.11312

PDF generated from XML JATS4R by Redalyc
Project academic non-profit, developed under the open access initiative

EDITORIAL

Chimeric antigen-receptor (CAR) T cells: The revtion of the cell and personalized therapy for cancer

Linfocitos T modificados con receptores quiméricos antígeno-específicos (CAR-T): la revolución de la terapia celular y personalizada para el cáncer

Javier Briones-Meijide [1]
Hospital Santa Creu i Sant Pau, Spain

Farmacia Hospitalaria, vol. 43, no. 6, 2019

Grupo Aula Médica

Received: 12 August 2019
Accepted: 20 August 2019

DOI: 10.7399/fh.11312

Copyright (c) 2019 Farmacia Hospitalaria
CC BY-NC-ND

Adoptive cell therapy (ACT) with mature T cells expressing chimeric antigen receptors (CARs) has revolutionized the field of ACT for cancer in the last years. CARs are composed of an antigen-specific binding domain encoding the variable regions of a monoclonal antibody, linked togetheinglhaintibodscFv)useransmembrane domain followed by cytoplasmic signaling domains[1] hilfirsenerationARontainenlnignaling domaiCDethain), the technology has evolved to incorporate additional signaling domains including costimulatory molecules (i.e., CD28, 4-1BB, OX40) to further enhance the activation of T cells (second and third generatioCARs). In the majority of situations, CAR T cells are autologous cells obtained from the own patient, activated ex vivo, modified with a viral vector encoding the CAR sequences and further expanded before being infused into the patientroceshaaas0-1ayexcluding qualitests)he development ohe so-called "second generation" CARS (mostly CD2r 4-1BB) represented a critical step towards an improvement of their clinical efficacy, especially in B-cell malignancies. Thus, treatment with a single dose of CAR T cells redirected to CD19 molecule (expressed in all B cell non-Hodgkin lymphomas-B-NHL- and acute lymphoblastic leukemia-B-ALL) (CART19esulteramatilinicaesponseatients witefractory B-ALL (80% complete responses, -CR-) and diffuse large B-cell lymphoma (DLBCL)hosrevalen-NHubtyp40R)[2,3]. These data, considerelinicabreakthrough" ehMpprovemenwo distinct CART19 therapies, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), foreeant of patients with relapse/refractory DLBCL) (both therapies) and pediatric/young adult (to 25 year-old) B- ALatientKymriah)hilheswherapierD1edirected, Kymriah is 4-1BB costimulated, while costimulation is provided by CD28 molecule in Yescarta's product. If this differenostimulatioraates into a clinical impact on the efficacy is not known yet, although some differences in toxicity may happen.

PDF generated from XML JATS4R by Redalyc
Project academic non-profit, developed under the open access initiative

However, this clinical success comes with a price, the development of potentially life-threatening complications: cytokine-release syndrome (CRS) anmmunffector-celeurotoxicityndromICANS)[4]. CRS is a very frequent complication (around 80% of patients) related to the in vivo expansion of T cells and cytokine production (most importantly IL-6 among others) which requires hemodynamic supportive treatment and use antibodies blocking IL- 6 (i.e., tocilizumab) and/or steroids. Although most of the cases resolved, a significant proportion of the patients (up to 30%) may need treatment in an intensive care unit. A second complication, the neurotoxicity syndrome, features different grades of encephalopathy although rare cases of fatal cerebral edema have occurred. These complications have led to the development of highly-multidisciplinary units for treating CART patients, including hematologists, neurologist, intensive medicine physicians, and pharmacists, all of which makes this therapy restricted to highly-specialized hospitals.

While CART19 is the most frequently used for hematological malignancies (> 20linicarials)ARargeting otheoleculerncreasingly being developed. The B-cell Maturation Antigen (BCMA) is expressed in the majority of multiple myeloma cells, and different CARs targeting BCMA have already entered into clinical trials. Similar to what has been found with CART19, highly-refractory myeloma patients (> 3 lines of previous treatment) had a response rate of 80% with almost half being CRs[5]. Such a response rate was rarely seen with other therapies on a group of patients with similar features.

Other CARs were developed to target Hodgkin lymphoma and myeloid malignancies. A CAR targeting CD30 (expressed in all Hodgkin tumor cells) was tested in two small clinical trials with some 30% CRs[6], and a clinical trial with a novel CART30 developed by our group at Hematology-Sant Pau is expected to start late this year after approval by AEMPS. In contrast to the success of CART19 for B-cell lymphoma and B-ALL, CARs for acute myeloid leukemia (AML) has been more difficult to developed, due to the absence of true tumor antigens not expressed on normal hemopoietic stem cells. CARs targeting AML tumor antigens is an area of intensive research for patients with refractory AML, a situation that represents a true unmet medical need.

Despite clinical success with CART19 and CART BCMA, almost 50% of patients do not benefit from this therapy at this moment, either because do not initially respond or because they relapse. Thus, it is clear that there is a lot of room for improvement and, as for other therapies, knowledge of predictor'actoresponsnesistance'echanismagerly awaited. In this line, preliminary clinical data shows that in vivo persistence of CART cells may be related to improved clinical response, and the proportion of particular T cell subsets (i.e., memory T cells) in the infused product may be associated with clinical outcome. For this reason, there is an intensive research on the methods used for ex vivo T cell expansion trying to preserve those less differentiated memory T cell subsets that may enhance the antitumor effect[7]. Other areas of active

PDF generated from XML JATS4R by Redalyc
Project academic non-profit, developed under the open access initiative

research include the development of CARs that secrete cytokines that further enhance the cytotoxiffecellnthemmunelli.e.L-12L-18)ho-called fourtenerationarmoredARslinicarials withesoveesig have been already started for patients with lymphoid malignancies, and it is expected to improve the response rate.

A novel concept that it is being tested recently is the use of the CART itself as a platform to secrete antitumor agents directly into the tumor microenvironment. In this sense, CARs can be designed to incorporate drugs in the format of DNA that, after protein translation, can be released upon stimulation with the tumor cells within the microenvironment, thus augmenting their efficacy while minimizing toxicities, an idea that led to the concept of CARs a minipharmacies". A soundiexample of this concept is the design of CARs with DNA sequences encoding antibodies either targeting tumor antigens or immunosupressive checkpoint molecules (i.e., anti-PD-1) which has been tested already in preclinical models[8].

The success of CART19 for some hematological malignancies has encouraged the application of CART for solid tumors. Despite being developed clinical trials with CARTs targeting a number of different antigens in a numbeumorsikisialogangliosidGD2)nterleukin1eceptor α 2, mucin-1, human epidermal growth factor receptor 2, and several others, the efficacy was modest[9]. Several challenges must be surmounted, such efficient trafficking of CART cells to tumors and overcoming immunosuppression in order to make this therapy successful for solid tumors.

CART therapy not only has brought a new form of therapy to the field of oncohematology, but also a different way of organization to make it available. The logistics required to provide this therapy are complex, and involve not only multidisciplinary clinical care teams but also the apheresis unit and pharmacy. Blood banks and the apheresis units are involved in critical steps of the production process, such as obtaining T cells for CART production, cryopreservation and shipping to the manufacturer center, and reception of the cryopreserved CART product until infusion to the patient. All of these procedures should be implemented with the highest standards of quality since may ultimately affect the performance of the product.

The pharmacy has a very important role in the coordination of the entire process. Pharmacist play a critical role in providing access to all drugs needed for the treatment of CART complications, some of them of new indicatioi.e.ocilizumab)nreatrotocols for urgent deliverf these drugs at any time. On the other hand, since CART cells are medicinal products, pharmacist must guarantee traceability and validation of the cells until the moment of the administration, which may represent a new task within their responsibilities. In this regard, the extensive experience gained by the hematology and blood bank departments with cells for hematopoietic transplantation should serve as a good platform to introduce the hospital pharmachineorldhellulaherapy.

PDF generated from XML JATS4R by Redalyc
Project academic non-profit, developed under the open access initiative

References

June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018;379(1):64-73.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-38.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D. Anti-BCMA CAR TCell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726-37.

Grover NS, Savoldo B. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019;19(1):20.

Alvarez-Fernández C, Escribà-Garcia L, Vidal S, Sierra J, Briones J. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy. J Transl Med. 2016;14(1):214.

Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1- blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847-56.

Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD Jr. Driving cars to the clinic for solid tumors. Gene Ther. 2018 ;25(3):165-75.

Author notes

Author of correspondence Correo electrónico: JBriones@santpau.cat (Javier Briones Meijide).

PDF generated from XML JATS4R by Redalyc
Project academic non-profit, developed under the open access initiative